Beam Therapeutics to present BEAM-302 trial data at ERS 2026

July 23, 2026 7:00 AM

Beam Therapeutics Inc. (Nasdaq: BEAM) announced it will present updated clinical data from its Phase 1/2 trial of BEAM-302, a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found